Physician profile
William Pierre Robert
NPI 1588624506
$1,921.19
in general payments reported to CMS, 2019-2025
19 companies · $143 in 2025
The $143 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $563 · 2020: $171 · 2021: $358 · 2022: $153 · 2023: $422 · 2024: $112 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $676.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $423.91 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $405.18 | 2021-2025 | Qelbree, Qelbree |
| Neos Therapeutics, LP | $143.10 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $135.50 | 2019-2024 | Jornay Pm |
| Sanofi Pasteur INC. | $125.99 | 2019-2024 | |
| Cranial Technologies, INC | $104.91 | 2019-2025 | Doc Band |
| Pfizer INC. | $90.92 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.34 | 2019-2021 | |
| Corium, LLC | $80.37 | 2022-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $60.28 | 2021-2023 | M-M-R II, Gardasil 9, Vaxelis |
| Arbor Pharmaceuticals, INC. | $57.10 | 2019 | |
| Alk-Abello, INC | $48.56 | 2021-2025 | Neffy, Odactra, Grastek |
| Genentech USA, INC. | $37.58 | 2020 | |
| Immedica Pharma US, INC. | $34.82 | 2023 | |
| Acadia Pharmaceuticals INC | $28.75 | 2025 | Daybue |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $19.16 | 2023 | Flucelvax Quadrivalent |
| Phadia US INC. | $17.62 | 2023 | Immunocap |
| Galderma Laboratories, L.P. | $14.71 | 2019 | |
| Glaxosmithkline, LLC. | $11.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Robert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.